Revolution Medicines

RVMD Lead: Approved 2 Biotech Distilled articles ↓

Most recent annual filing: 2026-02-25

Catalyst timeline

RASolve 301 daraxonrasib enrollment done2026RASolve 301 daraxonrasib enrollment done, 2026, routine
RASONQUE daraxonrasib corporate update3Q 2026RASONQUE daraxonrasib corporate update, 3Q 2026, material
RMC-5127 readout2H 2026RMC-5127 readout, 2H 2026, notable
pharma tariffs Section 232 FDASep 29, 2026pharma tariffs Section 232 FDA, Sep 29, 2026, material
RASolve 307 / elironrasib trial4Q 2026RASolve 307 / elironrasib trial, 4Q 2026, notable
RM-055 trial start4Q 2026RM-055 trial start, 4Q 2026, notable
RVMD commercial print launchNov 2026RVMD commercial print launch, Nov 2026, notable
RASolve 301 daraxonrasib topline2027RASolve 301 daraxonrasib topline, 2027, major
RMC-5127 RASolve readout2027RMC-5127 RASolve readout, 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (10 active programs)

RASONQUE

daraxonrasib · RMC-6236

Small Molecule Target: RAS, KRAS G12, RAS(ON)

Pancreatic Ductal Adenocarcinoma Approved oral BeOne Medicines NCT05379985
Non-Small Cell Lung Cancer NDA Submitted oral BeOne Medicines NCT05379985

zoldonrasib

RMC-9805

Small Molecule Target: KRAS G12D, RAS G12D, RAS(ON) G12D

Pancreatic Ductal Adenocarcinoma Phase 3 oral BeOne Medicines NCT07621718
Non-Small Cell Lung Cancer Phase 3 oral BeOne Medicines NCT07777822

elironrasib

RMC-6291

Small Molecule Target: KRAS G12C, RAS(ON) G12C

Non-Small Cell Lung Cancer Phase 3 oral BeOne Medicines NCT05462717
Colorectal Cancer Phase 1 oral BeOne Medicines NCT05462717

RMC-5127

Small Molecule Target: KRAS G12V, RAS(ON) G12V, RAS

Undisclosed indication Phase 1 oral BeOne Medicines

RMC-0708

Small Molecule Target: KRAS Q61H

Undisclosed indication Preclinical oral

RMC-8839

Small Molecule Target: KRAS G13C

Undisclosed indication Preclinical oral

RM-055

Target: RAS

Undisclosed indication

Technology platforms

tri-complex technology platform

Proprietary tri-complex platform enabling inhibition of the active GTP-bound form of RAS (RAS(ON)); used to design small molecule RAS(ON) inhibitors targeting multiple oncogenic RAS variants across cancer indications including PDAC, NSCLC, and CRC

Targets: RAS

Biotech Distilled coverage (2)

2026-09-15 UPDATE: Revolution Medicines (RVMD) - The FDA Just Tipped Its Hand on Front-Line 🔒 Paid
2026-08-27 Revolution Medicines (RVMD) — Scientific Deep Dive for RASONQUE (daraxonrasib) and the RAS(ON) Pipeline 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.